예측 기간 동안 주요 8개국(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 호주, 캐나다, 미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 호주, 캐나다)의 오피오이드 중독 치료 사례는 전반적으로 증가할 것으로 예상됩니다. 주요 8개국 시장의 오피오이드 중독 치료 건수는 예측 기간 동안 1,598,571건에서 1,821,677건으로 증가할 것이며, OUD는 59.1%, OWS는 40.9%를 차지할 것으로 예상됩니다.
주요 8개국 전체 오피오이드 중독 시장 규모는 2023년 기준 20억 달러로 평가되었으며, 10년간 연평균 1.8% 성장하여 2033년에는 24억 달러에 달할 것으로 예상됩니다.
예측 기간 동안 성장의 주요 요인은 가장 큰 오피오이드 중독 시장인 미국에서 모든 오피오이드 중독 환자 부문(경증, 중등도, 중증, OWS)의 총 치료 사례 수가 증가한다는 점입니다. 파이프라인 의약품의 도입도 오피오이드 중독 시장의 성장 촉진요인 중 하나입니다. AphioTx Inc.의 Probenecid, Ananda Scientific의 Cannabidiol, Trevena Inc.의 TRV-734, NLS Pharmaceutics의 Mazindol CR이 차례로 출시될 예정입니다.
이 보고서는 주요 8개국(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 호주, 캐나다, 미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 호주, 캐나다)의 오피오이드 중독 시장을 조사했으며, 질병 개요, 치료 옵션, 미충족 수요와 기회, 파이프라인 평가 등을 제공합니다.
목차
목차
제1장 서문
제2장 주요 요약
제3장 질환 개요
제4장 역학
제5장 현재의 치료 옵션
- 오피오이드 중독 치료 패러다임
- 치료 패러다임
- 오피오이드 중독 치료 전략 타임라인
- 현재 치료 옵션
- 제품 개요 : Oral Methadone Hydrochloride (Methadose, Methaddict)
- 제품 개요 : Morphine Sulfate ER (Substitol)
- 제품 개요 : Naltrexone ER (Vivitrol)
- 제품 개요 : Oral Naltrexone (Revia)
- 제품 개요 : Oral Buprenorphine (Subutex)
- 제품 개요 : Buprenorphine + Naloxone ODT (Zubsolv)
- 제품 개요 : Oral Buprenorphine + Naloxone (Suboxone)
- 제품 개요 : Buprenorphine LA (Sublocade)
- 제품 개요 : Buprenorphine Implant (Probuphine, Sixmo)
- 제품 개요 : Buprenorphine PR (Buvidal, Brixadi)
- 제품 개요 : Lucemyra (lofexidine)
- 환자 플로우 : 2023년 주요 8개국 시장의 오피오이드 중독
제6장 미충족 요구와 기회
- 오피오이드 중독 미충족 요구
- 오피오이드와 동등 유효성 프로파일을 가진 비오피오이드
- 현실 세계의 시나리오를 반영한 임상시험 설계
- 처방의 의식 향상과 교육
- 디지털 치료와 추가 행동 개입 제공에 따른 컴플라이언스 비율 향상
제7장 연구개발 전략
- 오피오이드 중독 임상시험 디자인 동향
- 오피오이드 중독 거래 동향
제8장 파이프라인 평가
- 오피오이드 중독 파이프라인 개요
- 오피오이드 중독에 대한 후기 파이프라인 의약품제
- 제품 개요 : Ananda Scientific's Cannabidiol
- 제품 개요 : NLS Pharmaceutical's Mazindol CR
- 제품 개요 : AphioTx Inc.'s Probenecid
- 제품 개요 : Trevena Inc.'s TRV-734
- 오피오이드 중독 : 임상시험(제II/III상) 개요
제9장 시장 전망
- 오피오이드 중독 시장 예측
- 시장 성장 촉진요인과 억제요인
제10장 부록
제11장 문의
LSH
There will be an overall increase in the treated cases of opioid addiction in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Australia, and Canada) across the forecast period. The total treated cases of opioid addiction in the 8MM will increase from 1,598,571 cases to 1,821,677 cases over the forecast period, 59.1% with OUD and 40.9% with OWS.
The Opioid Addiction market across the 8MM was valued at $2.0 billion in the 2023 baseline year. Over the 10-year forecast period, the market is projected to grow at a compound annual growth rate (CAGR) of 1.8%, reaching $2.4 billion by 2033.
The main driver of growth over the forecast period will be the increase in the number of total treated cases in the US, the largest opioid addiction market, across all of the opioid addiction patient segments (mild, moderate, severe, and OWS). The introduction of pipeline agents is another driver of growth within the opioid addiction market. In order of entry, these products will be AphioTx Inc.'s Probenecid, Ananda Scientific's Cannabidiol, Trevena Inc.'s TRV-734, and NLS Pharmaceutics Mazindol CR.
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Australia and Canada) and provides an Excel-based forecast model for the Opioid Addiction market through 2033.
Scope
- Overview of opioid addiction, inclusive opioid use disorder (OUD) and opioid withdrawal syndrome (OWS), including epidemiology, symptoms, diagnosis, and disease management.
- Annualized opioid addiction therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the opioid addiction market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for opioid addiction. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the 8MM opioid addiction therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 8MM opioid addiction therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the opioid addiction therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
Table of Contents
1. Preface
- 1.1. Contents
- 1.2. Abbreviations
- 1.3. Related Reports
2. Executive Summary
3. Disease Overview
- 3.1. Overview of Opioid Addiction: Opioid Use Disorder
- 3.2. Classification of Opioid Use Disorder
- 3.3. Overview of Opioid Withdrawal Syndrome
- 3.4. Pathophysiology of Opioid Addiction
- 3.5. Opioid Addiction SWOT Analysis
4. Epidemiology
- 4.1. 12-Month Total Prevalent Cases of OUD, Men and Women, Ages >=18 Years, 2023-33
- 4.2. Age-Specific Trends in 12-Month Total Prevalent Cases of OUD, Both Sexes, 2023
- 4.3. Sex-Specific 12-Month Total Prevalent Cases of OUD, Ages >=18 Years, 2023
- 4.4. 12-Month Total Prevalent Cases of OUD by Severity, Both Sexes, Ages >=18 Years, 2023
- 4.5. 12-Month Diagnosed Prevalent Cases of OUD, Men and Women, Ages >=18 Years, 2023-33
- 4.6. Age-Specific Trends in 12-Month Diagnosed Prevalent Cases of OUD, Both Sexes, 2023
- 4.7. Sex-Specific 12-Month Diagnosed Prevalent Cases of OUD, Ages >=18 Years, 2023
- 4.8. 12-Month Diagnosed Prevalent Cases of OUD by Severity, Both Sexes, Ages >=18 Years, 2023
- 4.9. 12-Month Total Prevalent Cases of OWS, Men and Women, Ages >=18 Years, 2023-33
- 4.10. 12-Month Diagnosed Prevalent Cases of OWS, Men and Women, Ages >=18 Years, 2023-33
- 4.11. Sources Used to Forecast 12-Month Total Prevalent Cases of OUD
- 4.12. Sources Used to Forecast 12-Month Total Prevalent Cases and 12-Month Diagnosed Prevalent Cases of OUD by Severity
- 4.13. Sources Used to Forecast 12-Month Total Prevalent Cases and 12-Month Diagnosed Prevalent Cases of OWS
- 4.14. Sources and Methodology
5. Current Treatment Options
- 5.1. Treatment Paradigm for Opioid Addiction
- 5.2. Treatment Paradigm
- 5.3. Timeline of Opioid Addiction Treatment by Strategy
- 5.4. Current Treatment Options
- 5.5. Product Profile: Oral Methadone Hydrochloride (Methadose, Methaddict)
- 5.6. Product Profile: Morphine Sulfate ER (Substitol)
- 5.7. Product Profile: Naltrexone ER (Vivitrol)
- 5.8. Product Profile: Oral Naltrexone (Revia)
- 5.9. Product Profile: Oral Buprenorphine (Subutex)
- 5.10. Product Profile: Buprenorphine + Naloxone ODT (Zubsolv)
- 5.11. Product Profile: Oral Buprenorphine + Naloxone (Suboxone)
- 5.12. Product Profile: Buprenorphine LA (Sublocade)
- 5.13. Product Profile: Buprenorphine Implant (Probuphine, Sixmo)
- 5.14. Product Profile: Buprenorphine PR (Buvidal, Brixadi)
- 5.15. Product Profile: Lucemyra (lofexidine)
- 5.16. Patient Flow: Opioid Addiction in 2023 Across the 8MM
6. Unmet Needs and Opportunities
- 6.1. Unmet Needs in Opioid Addiction
- 6.2. Non-Opioid with an Opioid-Comparable Efficacy Profile
- 6.3. Designing Clinical Trials Reflective of Real-World Scenarios
- 6.4. Greater Awareness and Education of Prescribers
- 6.5. Improving Compliance Rates Through the Offer of Digital Therapeutics and Additional Behavioral Interventions
7. R&D Strategies
- 7.1. Trends in Clinical Trial Design in Opioid Addiction
- 7.2. Trends in Deal-Making in Opioid Addiction
8. Pipeline Assessment
- 8.1. Opioid Addiction Pipeline Overview
- 8.2. Late-Stage Pipeline Agents for Opioid Addiction
- 8.3. Product Profile: Ananda Scientific's Cannabidiol
- 8.4. Product Profile: NLS Pharmaceutical's Mazindol CR
- 8.5. Product Profile: AphioTx Inc.'s Probenecid
- 8.6. Product Profile: Trevena Inc.'s TRV-734
- 8.7. Opioid Addiction: Clinical Trials (Phase II/III) Overview
9. Market Outlook
- 9.1. Opioid Addiction Market Forecast
- 9.2. Market Drivers and Barriers
10. Appendix
- 10.1. Primary Research: KOL Information
- 10.2. Bibliography
- 10.3. About the Authors
11. Contact Us
